Phase I clinical trial - Phases précoces tumeurs solides

MCLA-158-CL01
Phases précoces tumeurs solides
Essai clinique fermé
Public cible
Adulte
Phase 1 Dose Finding Study Evaluating the Bispecific Antibody MCLA-158 in Metastatic Colorectal Cancer and Other Advanced Solid Tumors.
Description de l'essai
This is a Phase I, open-label, multi-center, multi-national, dose escalation, single agent study to determine the recommended Phase II dose (RP2D) of MCLA-158 in metastatic colorectal cancer (mCRC). The study will assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158 in mCRC and other advanced solid tumors.
Vignette
CHRISTOPHE LE TOURNEAU
Investigateur principal